ZW209 — IND submission
in 2026
We anticipate submitting an IND to commence Phase 1 clinical studies for ZW209 in 2026, with equivalent non-U.S. applications to be submitted thereafter.Source filing
ZYME biotech catalysts & pipeline
ZYMEWORKS INC · Data as of 2026-09-08
Upcoming catalysts
EmpowHER-303 — Topline data
Jan 2027–Apr 2028
In January 2026, Jazz updated enrollment guidance for EmpowHER-303 in which they expect to complete enrollment in the first half of 2027, with a top-line data readout later in 2027 or in early 2028.Source filing
ZW1528 — IND submission
in 2027
We anticipate submitting a regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2027.Source filing
EmpowHER-303 — Topline data
Sep 2027–Apr 2028
The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028.Source filing
pasritamig — Topline data
Dec 2027
The anticipated primary completion date is now estimated as December 2027, compared with the previously estimated May 2028 date (NCT07164443).Source filing
pasritamig — Conference presentation
H2 2026
Johnson and Johnson Innovative Medicine (J&J) expect to present Phase 1b clinical data for pasritamig, a first-in-class bispecific antibody against KLK2, in combination with JNJ-9401 in patients with advanced prostate cancer who have progressed after multiple lines of therapy, during the second half of 2026.Source filing